Wave-Life-Sciences on Bioeconhttps://en.bioecon.ru/companies/wave-life-sciences/Recent content in Wave-Life-Sciences on BioeconHugoen-USThu, 23 Jul 2026 19:06:37 +0700RNA editing (ADAR) therapeuticshttps://en.bioecon.ru/technology/rna-editing-adar-therapeutics/Thu, 23 Jul 2026 00:00:00 +0000https://en.bioecon.ru/technology/rna-editing-adar-therapeutics/Engineered oligonucleotides that recruit the cell’s endogenous ADAR enzymes to rewrite a pathogenic adenosine to inosine on disease transcripts — a reversible, titratable alternative to DNA editing now in clinical validation, with Wave’s WVE-006 (AATD, RestorAATion-2) the lead asset and ProQR’s Axiomer platform delivering the first clinical proof of mechanism.